Cellectis announces an acceleration of its strategic refocusing on therapeutics and agrobusiness

Regulatory News:

Cellectis SA (Alternext:ALCLS) is looking to accelerate its strategic refocusing on therapeutics and agrobusiness through a large scale reorganization.

Since 2010, a sudden and spectacular paradigm shift has been radically changing business models across the entire biotech industry.

Since the beginning of the year, sales of genome engineering tools for research, which represented a sizeable proportion of the Group’s revenues, has faced strong competitive pressure throughout the world and particularly in the North American market. This turnaround has led to a substantial operating loss for that division, which has had an impact on the Group’s overall earnings.

At the same time, Cellectis’ therapeutics and agrobusiness activities have made significant strides forward in their development plan over the same period.

This situation leads Cellectis to look to adjusting its structure so as to meet its strategic targets to build value in the short and mid-term. Alongside an operating cost reduction program, the Company would focus its human and financial resources on its two strategic fields, while maintaining a service business that would be essentially dedicated to the bio-pharmaceutical industry.

Employee representatives will be made aware of and duly consulted on this plan that could result in a significant decrease in the Group’s workforce in France.

Once completed, aside from reducing operating costs by approximately €10 million on a full-year basis, this restructuring program should enable the Group to simplify its operations and become more competitive in its strategic growth fields.

About Cellectis

Founded in Paris in 1999, the Cellectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Cellectis was co-founded by André Choulika, its Chairman and CEO, and David Sourdive, Executive Vice President Corporate Development, and is now one of the world’s top companies in the field of genome engineering, with revenue of €21 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, toxicity testing, and regenerative medicine.

The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. Our clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.

For more information, visit our website: www.cellectis.com